All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression kidney transplant recipients obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline solid cancer solid organ transplant recipients subjects at risk
vaccines in COVID-19 prophylaxis (children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias confirmed Covid-19, from 1st dosedetailed results C4591001 (Adolescents 12-25), 2021 0.08 [0.02; 0.34]
June, 2021 0.09 [0.08; 0.10]
0.09 [0.08 ; 0.10 ] C4591001 (Adolescents 12-25), 2021, June, 2021 2 0% 1,304,680 NA not evaluable confirmed COVID (any severity)detailed results Glatman-Freedman A, 2021 0.09 [0.06; 0.12]
June, 2021 0.01 [0.00; 0.05]
kidCOVE (part 2), 2022 0.26 [0.16; 0.42]
Lutrick (PROTECT study), 2021 0.08 [0.03; 0.21]
PREVENT-19 adolescents, 0 0.18 [0.05; 0.68]
Reis, 2021 0.10 [0.08; 0.12]
Tartof, 2021 0.09 [0.07; 0.12]
teenCOVE (P203) (Adolescents 12-17Y), 2021 0.07 [0.01; 0.46]
Veneti, 2022 0.09 [0.07; 0.13]
Walter E.B. (Children <12 Years of Age), 2021 0.09 [0.03; 0.32]
0.10 [0.08 ; 0.13 ] Glatman-Freedman A, 2021, June, 2021, kidCOVE (part 2), 2022, Lutrick (PROTECT study), 2021, PREVENT-19 adolescents, 0, Reis, 2021, Tartof, 2021, teenCOVE (P203) (Adolescents 12-17Y), 2021, Veneti, 2022, Walter E.B. (Children <12 Years of Age), 2021 10 64% 1,311,844 NA low hospitalizationdetailed results Klein ( VISION network), 2022 0.26 [0.05; 1.35]
Olson (July to October), 2022 0.05 [0.03; 0.09]
Olson (June to September), 2021 0.09 [0.03; 0.26]
Price, 2022 0.17 [0.12; 0.24]
Tartof, 2021 0.19 [0.02; 1.67]
0.11 [0.06 ; 0.23 ] Klein ( VISION network), 2022, Olson (July to October), 2022, Olson (June to September), 2021, Price, 2022, Tartof, 2021 5 70% NA not evaluable symptomatic Covid-19detailed results C4591001 (Adolescents 12-25), 2021 0.03 [0.00; 0.50]
kidCOVE (part 2), 2022 0.12 [0.04; 0.32]
Klein ( VISION network), 2022 0.54 [0.43; 0.67]
Reis, 2021 0.07 [0.04; 0.14]
0.13 [0.03 ; 0.55 ] C4591001 (Adolescents 12-25), 2021, kidCOVE (part 2), 2022, Klein ( VISION network), 2022, Reis, 2021 4 93% 5,985 NA not evaluable asymptomatic COVID casedetailed results kidCOVE (part 2), 2022 0.38 [0.20; 0.69]
0.38 [0.20 ; 0.69 ] kidCOVE (part 2), 2022 1 0% 4,002 NA not evaluable ICU admissiondetailed results Olson (July to October), 2022 0.02 [0.01; 0.05]
0.02 [0.01 ; 0.05 ] Olson (July to October), 2022 1 0% NA not evaluable infection (PCR positive symptomatic or not)detailed results June, 2021 99.10 [98.60; 99.60]
99.10 [98.60 ; 99.60 ] June, 2021 1 0% NA not evaluable severe COVID-19 occurrencedetailed results Price, 2022 0.04 [0.02; 0.09]
0.04 [0.02 ; 0.09 ] Price, 2022 1 0% NA not evaluable vaccine efficacy after dose 1 (and before dose 2)detailed results C4591001 (Adolescents 12-25), 2021 0.25 [0.05; 1.13]
June, 2021 91.10 [89.66; 92.56]
5.01 [0.02 ; 1627.08 ] C4591001 (Adolescents 12-25), 2021, June, 2021 2 98% 2,239 low not evaluable 0.0 200.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-17 20:34 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 330
- treatments: 551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803
- roots T: 290
